Skip to main content

Table 2 Clinical and parasitological efficacy

From: Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial

PCR-corrected failure rates

A/L

Quinine

A/P

Clinical failure rate day 7

0/30

0/35

0/32

Parasitological failure rate day 7

0/30

0/35

0/32

Intention to treat failure rate* day 7

0/30

1/35 (~3%)

0/32

Clinical failure rate day 28

0/30

3/35 (~9%)

1/32 (~3%)

Parasitological failure rate day 28

0/30

3/35 (~9%)

2/32 (~6%)

Intention to treat failure rate* day 28

0/30

7/35 (~20%)

4/32 (~13%)

Recurrent parasitaemia

   

Number of patients with recrudescence** (day)

1 (70)

4 (24, 28, 28, 40***)

2 (28, 28)

Number of patients with new infection** (day)

1 (73)

4 (34, 40, 40***, 65)

1 (80)

Number of patients with P. vivax infection (day)

2 (28, 28)

5 (22, 25, 27, 28, 28)

2 (28, 28)

Gametocytaemia

   

Number of patients on day 0

1

3

1

Number of patients on day 7

2

10

16

Number of patients on day 28

0

2

0

  1. * lost to follow-up included
  2. **P. falciparum: Genotyping by PCR and RFLP patterns of the MSP-1 and MSP-2 gene
  3. *** One sample showed two different clones on day 40, one of them corresponded to the clone on day 0.